ALX Share Price

ALX Share Price

NASDAQ: ALXO | Micro Cap | Healthcare
$1.06
+$0.04 (3.41%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

ALX Stock Performance

Open
$1.02
Prev. Close
$1.02
Circuit Range
N/A
Day Range
$1.02 - $1.10
Year Range
$0.87 - $2.66
Volume
48,250
Average Traded
$1.06

ALX Share Price Today

As of 21 November 2026, ALX Oncology Holdings Inc.'s share price is $1.06. The stock opened at $1.02, compared to its previous close of $1.02. During today's trading session, ALX Oncology Holdings Inc.'s share price traded between $1.02 and $1.10, with an average price of $1.06. Over the past 52 weeks, the stock has recorded a high of $2.66 and a low of $0.87. In terms of performance, ALX Oncology Holdings Inc.'s share price has declined by 44.79% over the last six months and is down 22.34% on a year-on-year basis.

ALX Share Price Chart

Line chart of the ALX price trend over the selected period. The price rose overall, ranging from 1.02 to 1.10, ending at 1.06.
$1.02$1.10
L
Show Current Price
H

ALX Stock Fundamentals & Key Indicators

Market Cap
$56.88M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.62
Revenue (TTM)
$0.00
Return On Equity (TTM)
-64.02%
Profit Margin
N/A
Debt to Equity
0.08
Quarterly Earnings Growth YoY
4.46%

ALX Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$22.85-$17.93-$17.97-$21.83
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A21.53%-0.22%-21.48%

ALX Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$123.48-$160.81-$134.85-$101.70
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-30.23%16.14%24.58%

ALX Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets8.3213.4253.8935.52
Current Assets50.73134.35188.66270.97
Total Assets59.05147.78242.55306.49
Non Current Liabilities8.5115.6616.8414.7
Current Liabilities24.5518.536.028.33
Total Liabilities33.0734.1652.8443.03
Shareholders' Equity25.98113.62189.71263.46

ALX Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-84.14-121.91-130.36-89.22
Investing82.5986.2644.66-235.42
Financing0.3630.8259.299.86

About ALX

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

ALX Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$1.23
$1.05
-13.88%
Oct 2026
$1.38
$1.23
-12.19%
Sep 2026
$1.94
$1.40
-31.95%
Aug 2026
$1.99
$2.05
+5.40%
Jul 2026
$2.04
$1.95
-6.04%
Jun 2026
$1.86
$2.07
+7.81%
May 2026
$1.75
$1.92
+12.94%
Apr 2026
$2.05
$1.70
-15.21%
Mar 2026
$2.09
$2.00
-5.42%
Feb 2026
$1.66
$2.12
+21.49%
Jan 2026
$1.12
$1.75
+53.74%
Dec 2025
$1.38
$1.14
-16.85%

ALX Share Price FAQs